Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3-ITD-Mutant Acute Myeloid Leukaemia.
Zicari S, Merlino G, Paoli A, Fiascarelli A, Tunici P, Bisignano D, Belli F, Irrissuto C, Talucci S, Cirigliano E, Iannitto ML, Bigioni M, Bressan A, Brzózka K, Ghiaur G, Bellarosa D, Binaschi M. Zicari S, et al. Among authors: fiascarelli a. J Cell Mol Med. 2024 Dec;28(23):e70235. doi: 10.1111/jcmm.70235. J Cell Mol Med. 2024. PMID: 39653657 Free PMC article.
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, Wittner BS, Rai S, Patel H, Bihani T, Arlt H, Bidard FC, Kaklamani VG, Aftimos P, Cortés J, Scartoni S, Fiascarelli A, Binaschi M, Habboubi N, Iafrate AJ, Toner M, Haber DA, Maheswaran S. Dubash TD, et al. Among authors: fiascarelli a. Breast Cancer Res Treat. 2023 Aug;201(1):43-56. doi: 10.1007/s10549-023-06998-w. Epub 2023 Jun 15. Breast Cancer Res Treat. 2023. PMID: 37318638 Free PMC article.
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
Fiascarelli A, Merlino G, Capano S, Talucci S, Bisignano D, Bressan A, Bellarosa D, Carrisi C, Paoli A, Bigioni M, Tunici P, Irrissuto C, Salerno M, Arribas J, de Stanchina E, Scaltriti M, Binaschi M. Fiascarelli A, et al. Breast Cancer Res Treat. 2023 May;199(1):13-23. doi: 10.1007/s10549-023-06895-2. Epub 2023 Mar 13. Breast Cancer Res Treat. 2023. PMID: 36913051 Free PMC article.
Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients.
Tosca EM, Borella E, Piana C, Bouchene S, Merlino G, Fiascarelli A, Mazzei P, Magni P. Tosca EM, et al. Among authors: fiascarelli a. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1626-1639. doi: 10.1002/psp4.12910. Epub 2023 Feb 15. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36793223 Free PMC article.
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas AJ, Cascione L, Bigioni M, Merlino G, Fiascarelli A, Bressan A, Adjeiwaa Mensah A, Golino G, Lucchini R, Bernasconi E, Rossi D, Zucca E, Stussi G, Stathis A, Boyd RS, Dusek RL, Bisht A, Attanasio N, Rohlff C, Pellacani A, Binaschi M, Bertoni F. Gaudio E, et al. Among authors: fiascarelli a. Haematologica. 2020 Nov 1;105(11):2584-2591. doi: 10.3324/haematol.2019.227215. Haematologica. 2020. PMID: 33131247 Free PMC article.
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M. Merlino G, et al. Among authors: fiascarelli a. Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21. Mol Cancer Ther. 2019. PMID: 31227646
Differential 3-bromopyruvate inhibition of cytosolic and mitochondrial human serine hydroxymethyltransferase isoforms, key enzymes in cancer metabolic reprogramming.
Paiardini A, Tramonti A, Schirch D, Guiducci G, di Salvo ML, Fiascarelli A, Giorgi A, Maras B, Cutruzzolà F, Contestabile R. Paiardini A, et al. Among authors: fiascarelli a. Biochim Biophys Acta. 2016 Nov;1864(11):1506-17. doi: 10.1016/j.bbapap.2016.08.010. Epub 2016 Aug 13. Biochim Biophys Acta. 2016. PMID: 27530298
A pyrazolopyran derivative preferentially inhibits the activity of human cytosolic serine hydroxymethyltransferase and induces cell death in lung cancer cells.
Marani M, Paone A, Fiascarelli A, Macone A, Gargano M, Rinaldo S, Giardina G, Pontecorvi V, Koes D, McDermott L, Yang T, Paiardini A, Contestabile R, Cutruzzolà F. Marani M, et al. Among authors: fiascarelli a. Oncotarget. 2016 Jan 26;7(4):4570-83. doi: 10.18632/oncotarget.6726. Oncotarget. 2016. PMID: 26717037 Free PMC article.
12 results